Deerfield Management Company, L.P. (Series C) Spruce Biosciences, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.04 Billion
Q4 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.33 - $5.74 $5.13 Million - $12.6 Million	-2,200,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.01 - $11.26 $919,782 - $1.72 Million	153,042 Added 7.48%	2,200,000 $13.2 Million
Q2 2021 Aug 16, 2021	BUY	$10.12 - $17.46 $20.7 Million - $35.7 Million	2,046,958 New	2,046,958 $22.9 Million

Others Institutions Holding SPRB

# of Institutions

Shares Held

15.9M

Call Options Held

Put Options Held

River Vest Venture Management LLC St. Louis, MO

2.94M
Shares

$1.23 Million
20.39% of portfolio
Carlyle Group Inc. Washington, DC

2.9M
Shares

$1.22 Million
1.19% of portfolio
Rock Springs Capital Management LP Baltimore, MD

2.61M
Shares

$1.1 Million
0.04% of portfolio
Abingworth LLP London, X0

1.79M
Shares

$752,857
0.65% of portfolio
Acadian Asset Management LLC Boston, MA

1.05M
Shares

$439,247
0.0% of portfolio

View Full List

About SPRUCE BIOSCIENCES, INC.

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $9.9M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

More about SPRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account